9 Pharmaceuticals Stocks to Sell Now

9 Pharmaceuticals Stocks to Sell Now

This week, 9 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) is having a tough week. The company’s rating falls from a D to a F. Teva Pharmaceutical Industries Limited Sponsored ADR is engaged in the provision of pharmaceutical services. For more information, get Portfolio Grader’s complete analysis of TEVA stock.

This is a rough week for Novo Nordisk A/S Sponsored ADR Class B (NVO). The company’s rating falls to D from the previous week’s C. Novo Nordisk A/S Sponsored ADR Class B develops, produces, and markets pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of NVO stock.

Dr. Reddy’s Laboratories Ltd. Sponsored ADR (RDY) declines this week from a D to a F. Dr. Reddy’s Laboratories Ltd. Sponsored ADR is a global company that produces and markets active pharmaceutical ingredients, intermediates, finished dosage forms, and biologic products. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of RDY stock.

This week, Sanofi Sponsored ADR (SNY) drops from a D to a F rating. Sanofi Sponsored ADR is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The company also gets F’s in sales growth. For more information, get Portfolio Grader’s complete analysis of SNY stock.

Egalet Corporation’s (EGLT) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EGLT stock.

KemPharm, Inc. (KMPH) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of KMPH stock.

AcelRx Pharmaceuticals, Inc. (ACRX) experiences a ratings drop this week, going from last week’s C to a D. AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACRX stock.

Ritter Pharmaceuticals, Inc. (RTTR) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RTTR stock.

Merus Labs International Inc. (MSLI) slips from a D to a F this week. Merus Labs International Inc. acquires and licenses niche branded pharmaceutical products in the United States and Canada. The company also gets F’s in earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of MSLI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/08/9-pharmaceuticals-stocks-to-sell-now-2/.

©2019 InvestorPlace Media, LLC